SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

2/9/23 8:23:46 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ACAD alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.17 ACADIA PHARMACEUTICALS INC COMMON STOCK Cusip #004225108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #004225108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 9,333,583 Item 6: 0 Item 7: 9,334,613 Item 8: 0 Item 9: 9,334,613 Item 11: 5.764% Item 12: HC Cusip #004225108 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 9,334,613 Item 8: 0 Item 9: 9,334,613 Item 11: 5.764% Item 12: IN Item 1(a). Name of Issuer: ACADIA PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 004225108 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 9,334,613 (b) Percent of Class: 5.764% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 9,334,613 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ACADIA PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of ACADIA PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing orinfluencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 9, 2023 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 9, 2023, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ACADIA PHARMACEUTICALS INC at December 30, 2022. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January, 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $ACAD alert in real time by email

Recent Analyst Ratings for

$ACAD

Date	Price Target	Rating	Analyst
3/25/2026	$29.00	Neutral → Buy	BofA Securities
2/24/2026	$33.00	Outperform	Wolfe Research
2/23/2026	$35.00	Neutral → Outperform	Mizuho
10/21/2025	$33.00	Buy	Citigroup
5/21/2025	$35.00	Hold → Buy	Deutsche Bank
2/11/2025	$22.00	Hold	Deutsche Bank
1/3/2025	$23.00 → $20.00	Buy → Neutral	Guggenheim
10/10/2024		Mkt Perform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

2/9/23 8:23:46 AM ET

$ACAD

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ACAD alert in real time by email

Recent Analyst Ratings for

$ACAD

Date	Price Target	Rating	Analyst
3/25/2026	$29.00	Neutral → Buy	BofA Securities
2/24/2026	$33.00	Outperform	Wolfe Research
2/23/2026	$35.00	Neutral → Outperform	Mizuho
10/21/2025	$33.00	Buy	Citigroup
5/21/2025	$35.00	Hold → Buy	Deutsche Bank
2/11/2025	$22.00	Hold	Deutsche Bank
1/3/2025	$23.00 → $20.00	Buy → Neutral	Guggenheim
10/10/2024		Mkt Perform	Raymond James

More analyst ratings

SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ACAD

SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ACAD

$ACAD
Insider Trading

Director Baker Bros. Advisors Lp was granted 37,244 shares (SEC Form 4)

Director Harrigan Edmund converted options into 8,107 shares, increasing direct ownership by 23% to 43,148 units (SEC Form 4)

Director Ndu Adora converted options into 8,107 shares, increasing direct ownership by 33% to 32,908 units (SEC Form 4)

$ACAD
Press Releases

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

$ACAD
FDA approvals

FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

FDA Approval for NUPLAZID issued to ACADIA PHARMS INC

$ACAD
Analyst Ratings

ACADIA Pharmaceuticals upgraded by BofA Securities with a new price target

Wolfe Research initiated coverage on ACADIA Pharmaceuticals with a new price target

ACADIA Pharmaceuticals upgraded by Mizuho with a new price target

$ACAD
SEC Filings

ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update

SEC Form 10-Q filed by ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$ACAD
Financials

Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

$ACAD
Leadership Updates

Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

$ACAD
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by ACADIA Pharmaceuticals Inc.

SEC Form SC 13G filed by ACADIA Pharmaceuticals Inc.